A high-level overview of Relmada Therapeutics, Inc. (RLMD) stock. View (RLMD) real-time stock price, chart, news, analysis, analyst reviews and more.

Grace says her dream is to tour, performing her music to live audiences and continuing to raise awareness about the condition ...

Tourette syndrome (TS) is more than just a childhood phase of twitching or making sounds—it’s a chronic neurodevelopmental condition that can disrupt daily functioning and emotional well-being.

More than 50,000 Australians have Tourette syndrome. A new report has highlighted the ongoing barriers those with the condition and other tic disorders face.

Baylen Dupree, 22, said she had to drop out of college due to her severe tic attacks. She opened up about her struggle with Tourette Syndrome at an FYC event for her TLC series "Baylen Out Loud ...

"We'd explain to customers (about Spinner's Tourette's Syndrome)," Crocitto said. "He got to the point where he carried skateboard as a symbol. Go around on it a few feet, then carry it." ...

The phase 3 D1AMOND trial (ClinicalTrials.gov Identifier: NCT05615220) evaluated the safety, tolerability, and efficacy of ecopipam in pediatric and adult participants with Tourette syndrome.

Emalex Biosciences announced positive topline results from a Phase III registrational study of its lead candidate ecopipam, a dopamine-1 receptor antagonist, for Tourette syndrome (TS). According to ...

The phase 3 study builds on Emalex’s prior phase 2 work, which found that ecopipam reduced tic severity by 30% after 12 weeks in 150 children and adolescents with Tourette syndrome.

Relmada Therapeutics has announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid developed for treating Tourette syndrome (TS) and related compulsive disorders, from Asarina Pharma ...

Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from Asarina Pharma AB Phase 2a results signaled ...